• SynAct Pharma posted a Q2 loss after tax of SEK 22.03 million, narrowing from SEK 27.52 million a year earlier.
• Operating expenses fell 19% year on year to SEK 24.56 million; net sales were unchanged at no revenue.
• Cash flow from operating activities widened to SEK -34.54 million from SEK -18.79 million, leaving cash at SEK 14.29 million.
• Management cited new capital secured and active partnering discussions; a term sheet was signed for a Brazil dengue agreement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SynAct Pharma AB published the original content used to generate this news brief on August 20, 2026, and is solely responsible for the information contained therein.